Skip to main content

Analysts Conflicted on These Healthcare Names: Crispr Therapeutics AG (CRSP) and Bruker (BRKR)

Tipranks - Tipranks - Sat Feb 14, 5:54AM CST

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Crispr Therapeutics AG (CRSP – Research Report) and Bruker (BRKR – Research Report).

Valentine's Day Sale - 70% Off

Crispr Therapeutics AG (CRSP)

Needham analyst Gil Blum maintained a Buy rating on Crispr Therapeutics AG today and set a price target of $82.00. The company’s shares closed last Thursday at $48.93.

According to TipRanks.com, Blum is a 4-star analyst with an average return of 6.6% and a 38.3% success rate. Blum covers the Healthcare sector, focusing on stocks such as Recursion Pharmaceuticals, Mereo Biopharma Group Plc, and Cartesian Therapeutics. ;'>

Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $75.00, representing a 54.1% upside. In a report issued on January 30, Citizens JMP also maintained a Buy rating on the stock with a $80.00 price target.

See the top stocks recommended by analysts >>

Bruker (BRKR)

In a report released yesterday, Daniel Brennan from TD Cowen maintained a Hold rating on Bruker, with a price target of $53.00. The company’s shares closed last Thursday at $37.51.

According to TipRanks.com, Brennan is a 5-star analyst with an average return of 19.2% and a 53.6% success rate. Brennan covers the Healthcare sector, focusing on stocks such as Caris Life Sciences, Inc., Adaptive Biotechnologies, and Tempus AI, Inc. Class A. ;'>

Bruker has an analyst consensus of Moderate Buy, with a price target consensus of $54.00.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).